VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
Summary
VelaVigo will maintain rights for Greater China.Under the terms of the agreement, VelaVigo will receive an upfront fee and future development, regulatory, and commercial milestone payments in cash and equity, totaling up to approximately $440 million in the aggregate, as well as tiered royalties on sales in Ollins territory.This milestone follows VelaVigos first licensing deal with Avenzo Therapeutics in November 2024 and the successful close of a $50 million Pre-A funding round in February 2025, reinforcing the companys unique business model combining business development (BD) and venture capital (VC) strategies for sustainable growth.The latest deal underscores VelaVigos ability to discover and develop high-potential therapeutics while partnering strategically to maximize value. The company will also present data on five additional FIC or BIC molecules at upcoming industry conferences, seeking further partnership opportunities worldwide. "This second out-licensing deal is a strong validation of our discovery platform and our ability to identify and advance novel therapeutics with significant potential," said Jing Li, CEO of VelaVigo. "With our first asset entering the clinic this year and a deep pipeline of innovative molecules, we are demonstrating our capacity to translate cutting-edge science into valuable clinical-stage programs. ""Our BD+VC model is designed to create sustainable value for investors and partners," said Tong Zhang, co-founder, Chief Business & Financial Officer of VelaVigo.